Pharmacogenetics (DPYD / UGT1A1 only)
DPYD and/or UGT1A1 pharmacogenetic testing for drug response and efficacy (Germline DNA).
Pharmacogenetics (panel testing)
Pharmacogenetic panel testing of markers for drug response and efficacy (Germline DNA).
NGS for somatic SNVs and indels – tumour with germline subtraction analysis
EQA for quality of NGS for somatic SNVs and indels <50bp (FFPE). For NGS requiring a matched normal control germline sample (single gene, panel testing, whole exome sequencing or whole genome sequencing). Pilot EQA.
NGS for somatic SNVs and indels – tumour testing only
EQA for quality of NGS for somatic SNVs and indels <50bp (FFPE). For NGS NOT requiring a matched normal control germline sample (single gene, panel testing, whole exome sequencing or whole genome sequencing). Pilot EQA.
Microsatellite Instability testing (MSI) [Tissue]
Microsatellite Instability testing testing (FFPE).
Oncogene panel testing [Tissue]
This EQA scheme is offered to help laboratories using high through put technologies (e.g., NGS, MassArray etc.) to accurately validate assay sensitivity and specificity. For specific tumour types, please register for the relevant scheme (e.g., Lung, Melanoma, Colorectal, Ovarian, Breast, Prostate, Pancreas). High quality reference materials are provided covering a range of genes with variants with ddPCR quantified allelic frequencies.